Skip to content

Inflammatory and Metabolic Outcomes After Obese Woman Performed High Intensity Interval Training

Inflammatory and Metabolic Outcomes in Obese Women After 8 Weeks of High Intensity Interval Training and Moderate Intensity Continuous Training: a Randomized Controlled Pilot Study

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03409172
Enrollment
48
Registered
2018-01-24
Start date
2016-06-01
Completion date
2018-01-08
Last updated
2018-01-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity and Metabolic Syndrome

Keywords

High intensity interval training, Inflammation, Obesity, adipokines

Brief summary

The main purpose of this study is to compare the effects of high intensity interval training and moderate intensity continuous training on inflammatory profile and metabolic markers, after 8 weeks of intervention trial in obese women.

Interventions

OTHERCTR

no counseling or nutritional therapy and no exercise

OTHERMICT

no counseling or nutritional therapy. 8 weeks of individualized and supervised ergometer-based moderate continuous intensity training (MICT).

OTHERHIIT

no counseling or nutritional therapy. 8 weeks of individualized and supervised ergometer-based high intensity interval training (HIIT)

Sponsors

University of Sao Paulo
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Masking description

Outcome Assessors involved in data analysis will not be aware of the arm to which the participants were allocated (single-blinded masking)

Intervention model description

Three-arm parallel, Randomized-controlled study

Eligibility

Sex/Gender
FEMALE
Age
25 Years to 41 Years
Healthy volunteers
No

Inclusion criteria

* Body Mass Index between (30-40 kg/m²) * age between 25 and 41 years * to be sedentary

Exclusion criteria

* type 1 or type 2 diabetes * Hypertension * pregnancy, Lactation * having undergone bariatric surgery * psychological disorders, epilepsy, sever neurological disorders * participation in other moderate, vigorous exercise or nutrition intervention * acute or chronic cardiovascular disease * malignant disease * kidney disease * lung disease * hyperthyroidism or hypothyroidism * smoking any type of cigarette * joint limitations * electronic implants (defibrillator, pacemaker)

Design outcomes

Primary

MeasureTime frameDescription
Inflammatory profile8 weeks (baseline to 8 week follow-up assessment)C-reactive protein (CRP) (mg/dL)

Secondary

MeasureTime frameDescription
Insulin sensitivity8 weeks (baseline to 8 week follow-up assessment) ]Insulin sensitivity was estimated using homeostasis model assessment index (HOMA)
Lipid profile8 weeks (baseline to 8 week follow-up assessment) ]Lipid profile was assessed by measuring levels of triglyceride (TG) (mg/dL), total cholesterol (CT) (mg/dL), high-density lipoprotein cholesterol (HDL-C) (mg/dL) and low-density lipoprotein cholesterol (LDL-C) (mg/dL)
Cardiorespiratory Fitness (CRF)8 weeks (baseline to 8 week follow-up assessment) ]CRF was assessed by measuring Peak Oxygen uptake (VO2peak) mL/kg/min
Body Composition and Anthropometric profile8 weeks (baseline to 8 week follow-up assessment) ]Body weight (kg), Fat free mass (FFM) (kg), fat mass (FM) (kg)
Resting Energy Expenditure (REE)8 weeks (baseline to 8 week follow-up assessment) ]Resting Energy Expenditure (kcal/day) was measured through indirect calorimetry with an open-circuit ventilated-hood system Substrate oxidation rate was calculated from VO2 (mL/min) and VCO2 (mL/min)
Substrate oxidation rate8 weeks (baseline to 8 week follow-up assessment) ]Substrate oxidation rate was calculated from VO2 (mL/min) and VCO2 (mL/min)
Blood Pressure (BP)8 weeks (baseline to 8 week follow-up assessment) ]Blood Pressure (mmHg) was assessed by measuring rest levels of Systolic blood pressure (SBP) and Diastolic blood pressure (DBP)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026